• Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital
• The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP)
• The mPTP is a well-established driver of mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases. NRG’s…
Pioneer Group, a specialist in life science infrastructure and venture building, has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.
The 2025 Golden Ticket Programme offers the opportunity for an early-stage biotech company to secure one year of funding for lab space, a £50,000 grant, mentorship and scientific expertise to support…
Bind Research and Twig Bio join LBIC at the Apex in King’s Cross, bringing LBIC’s space to over 50% occupancy just six months after launch.
Bind Research becomes The Apex’s first non-profit tenant, recently awarded major UK Government and partner funding.
LONDON, UK, 3rd September 2025: London BioScience Innovation Centre (LBIC) has welcomed two new tenants, Bind Research and Twig Bio, to its Apex facility in King’s Cross, reaching more than half its capacity within six months. The milestone validates LBIC’s growth strategy of providing state-of-the-art, fully fitted, grow-on laboratory…
Welcome to this month's eNews
Looking Forward to a Golden Autumn
Tony Jones, CEO, One Nucleus
Many look forward to the autumnal colours arriving as the seasons move along from summer breaks and a recharging of batteries in the sun. It’s no different at One Nucleus, where our team is excited to welcome its network back to our upcoming opportunities to engage, alongside some new initiatives and support supplier deals to roll out that have been ripening over the summer.
The financing environment remains challenging for many, as we are all aware, so one hopes the golden colours…
Pioneer Group, a specialist in life science infrastructure and venture building, has launched a new Accelerator Programme for early-stage life science companies targeting unmet needs in the management of chronic conditions.
Funded by the Innovate UK Biomedical Catalyst, in collaboration with the Medical Research Council, the Accelerator has been designed to support UK start-ups in the initial phases of their development.
Pioneer is inviting applications from companies targeting unmet needs in disease prevention or the proactive management, whether targeting a single health condition or…
Cambridge, UK: o2h Technology, a business vertical of the o2h Group, is delighted to announce the launch of the fourth edition of its Tech Kickstarter Competition. First launched in 2023, the initiative continues to support innovative seed and early-stage companies by helping them bring their ideas to life with end-to-end MVP, web, and mobile app development needs.Building on the success of earlier editions, the competition has already established itself as a catalyst for innovative seed and early-stage ventures. To date, it has attracted over 70 startup applications, with 9 winners selected…
CancerTools.org, a unique non-profit cancer research tool supplier and part of Cancer Research UK, has chosen Discovery Park as the home of their first UK based laboratory, growing their team at the Sandwich Science and Tech campus.
Since establishing its presence at Discovery Park in 2023, CancerTools.org has expanded its operations, enhancing its capacity to provide high-quality cancer research tools to the global scientific community. Many of these tools are contributed by leading academic laboratories and researchers, reflecting the organisation’s collaborative approach. The organisation…
New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior
End-to-end support from experimental design to data interpretation
Cambridge, UK, 02 September 2025: CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS) with new PhysioMimix® computational modeling tools. These capabilities have been developed to enhance Absorption, Distribution,…
Targeted protein degradation experts Prof. Alessio Ciulli FRS and Dr Adam Gilbert appointed
SAB will provide strategic and scientific perspectives to support development of TRIMTAC and TRIMGLUE selective targeted protein degraders, and small molecule therapeutic pipeline
Cambridge, UK, 02 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB). Globally recognised leaders within the protein…
Members of the Industry Skills Accelerator (ISA) have celebrated a successful year of strengthening the UK’s medicines manufacturing workforce.
Launched in August 2024 and funded by Innovate UK, the ISA is a national initiative delivered through a partnership between Cogent Skills, the Cell and Gene Therapy Catapult (CGT Catapult), and CPI (part of the High Value Manufacturing Catapult).
Focused on advanced therapies and complex medicines – including cell, gene, vaccines, biologics, and other high-potential modalities such as mRNA and Oligonucleotides - the ISA is building targeted training…